By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences today reported flat year-over-year second-quarter revenues and a slight increase in its net loss, as the firm continues studies of its stool-based DNA test for colorectal cancer.

The Madison, Wis.-based molecular diagnostics firm brought in a total of $1.3 million in revenues for the three-month period ended June 30, roughly flat with the second quarter of 2009. Almost the entirety of revenues came from license fees.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.